Previous 10 | Next 10 |
Alexion Pharmaceuticals (NASDAQ: ALXN ) initiated with Neutral rating and $135 (6% upside) price target at Guggenheim. More news on: Alexion Pharmaceuticals, Inc., Dermira, Exelixis, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
Intercept Pharmaceuticals ( ICPT ) recently reported interim results from its phase 3 REGENERATE study. It noted that it had met on one co-primary endpoint, but failed on another. The company will be able to file for FDA and EMA approval, but a few issues associated with the drug may not a...
NEW YORK, Feb. 20, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its fourth quarter and full year 2018 fi...
Gainers: Kandi Technologies Group (NASDAQ: KNDI ) +47% . LeMaitre Vascular (NASDAQ: LMAT ) +28% . AzurRx BioPharma (NASDAQ: AZRX ) +29% . Blink Charging (NASDAQ: BLNK ) +21% . Carrols Restaurant Group (NASDAQ: TAST ) +17% . OneSpan (NASDAQ: OSPN ) +17% . Garmin (NASDAQ: GRMN ) ...
Gilead Sciences (GILD) has a very tough road ahead after its latest earnings report. The earnings for the fourth quarter were mixed, but the company needs to take drastic action to redeem itself. The revenue may have come in over expectations, but it won't be long until Gilead finds itself i...
Intercept Pharmaceuticals ( ICPT +6.5% ) is up on almost a 12x surge in volume, although shares have retraced 11% from the intraday high of $131.87, following its announcement of positive results from a Phase 3 clinical trial evaluating top drug OCALIVA (obeticholic acid) i...
Bioblast Pharma (NASDAQ: ORPN ) +36% on announcing sale of Trehalose clinical development programs to Seelos Therapeutics. More news on: Bio Blast Pharma, Sky Solar Holdings, Intercept Pharmaceuticals, Stocks on the move, Read more ...
Intercept Pharmaceuticals (NASDAQ: ICPT ) is up 23% premarket on light volume following its announcement of positive results from a Phase 3 clinical trial, REGENERATE , evaluating obeticholic acid (OCA) in patients with liver fibrosis (scarring) due to nonalcoholic steatohepat...
First and largest successful pivotal Phase 3 study in patients with liver fibrosis due to NASH OCA achieves primary endpoint demonstrating statistically significant improvement in liver fibrosis without worsening of NASH at 18 months (p=0.0002) Intercept intends to file for regulat...
My previous article forecast problems for selonsertib, as new research indicates that this drug targets mouse-specific pathways that are not present in humans. NASH cirrhosis trials continue to struggle. Intercept’s Ocaliva, a “NASH cirrhosis” drug candidate, is haile...
News, Short Squeeze, Breakout and More Instantly...
Intercept Pharmaceuticals Inc. Company Name:
ICPT Stock Symbol:
NASDAQ Market:
Intercept Pharmaceuticals Inc. Website:
MORRISTOWN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced five abs...
sNDA intended to satisfy post-marketing requirements to confirm a clinical benefit in patients with PBC Precedent-setting submission includes data from post-marketing studies COBALT and Study 401 as well as real-world evidence from a claims database and patient registries FDA has assign...
Data from two Phase 2 studies in PBC show combination of OCA + bezafibrate achieved biochemical remission (normalization of ALP, total bilirubin, GGT, ALT and AST) in 40-44% of patients in the first 12 weeks OCA 5 or 5-10 mg + bezafibrate 400 mg cohorts in both studies showed a >60% ...